Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis

Respirology

Volumn 19, Issue 5, 2014, Pages 740-747

  Valeyre, Dominique ^a   Albera, Carlo ^b   Bradford, Williamson Z ^c   Costabel, Ulrich ^d   King, Talmadge E ^e   Leff, Jonathan A ^c   Noble, Paul W ^f   Sahn, Steven A ^g   Du Bois, Roland M ^h  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITY OF TURIN   (Italy)

^c InterMune Inc   (United States)

^d RUHRLANDKLINIK   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

adverse event; idiopathic pulmonary fibrosis; pirfenidone; safety; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE;

ADULT; AGED; BLOOD; DOSE RESPONSE; EVALUATION STUDY; FEMALE; HUMAN; IDIOPATHIC PULMONARY FIBROSIS; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84903166926     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12297     Document Type: Article

References (18)

1. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am. J. Respir. Crit. Care Med. 2000; 161: 646-664.
2. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DW, Noble PW, Raghu G, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 2005; 142: 963-967.
3. Iyer SN, Gurujeyalakshmi G, Giri SN,. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 1999; 291: 367-373. (Pubitemid 29451612)
4. Hirano A, Kanehiro A, Ono K, Ito W, Yoshida A, Okada C, Nakashima H, Tanimoto Y, Kataoka M, Gelfand EW, et al. Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am. J. Respir. Cell Mol. Biol. 2006; 35: 366-377. (Pubitemid 44353405)
5. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R,. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur. J. Pharmacol. 2002; 446: 177-185. (Pubitemid 34722572)
6. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R,. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol. 2002; 446: 167-176. (Pubitemid 34722571)
7. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A,. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008; 590: 400-408.
8. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN,. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 1995; 125: 779-785.
9. Iyer SN, Margolin SB, Hyde DM, Giri SN,. Lung fibrosis is ameliorated by pirfenidone fed in diet after second dose in a three-dose bleomycin-hamster model. Exp. Lung Res. 1998; 24: 119-132. (Pubitemid 28092539)
10. Iyer SN, Gurujeyalakshmi G, Giri SN,. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 1999; 289: 211-218. (Pubitemid 29156031)
11. Schelegle ES, Mansoor JK, Giri S,. Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc. Soc. Exp. Biol. Med. 1997; 216: 392-397.
12. Raghu G, Johnson WC, Lockhart D, Mageto Y,. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 1999; 159: 1061-1069. (Pubitemid 29202536)
13. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled, trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040-1047. (Pubitemid 40616955)
14. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al. Pirfenidone in idiopathic pulmonary fibrosis: a phase III clinical trial in Japan. Eur. Respir. J. 2010; 35: 821-829.
15. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1768.
16. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi R,. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2010; (9): CD003134. doi: 10.1002/14651858. CD003134.pub2.
17. Temple R,. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug Saf. 2006; 15: 241-243.
18. Esbriet. Summary of Product Characteristics. InterMune Europe Ltd, London, UK, 2011.